Thymosin Alpha-1: the immune system's slowest burn

The pitch for Thymosin Alpha-1 is the longevity-immune one. As you age, your thymus shrinks. Your T-cell repertoire narrows. Your immune system starts mounting weaker responses to new threats. A peptide your own thymus secretes — give it back, the marketing says, and you can push the clock back a notch.

The pitch is unusual for this corner of the market because the underlying biology actually checks out. The thymus does shrink with age. T-cell decline is real. Thymosin Alpha-1 is a real immunomodulatory peptide your body really makes.

What the marketing leaves out is the gap between Tα1 is an immune drug with a multi-decade clinical record and Tα1 is going to help a healthy fifty-year-old’s immune system. The first statement is true. The second has not been tested. Almost the entire human evidence base for Tα1 is in patients who are critically ill, immunocompromised, or both.

That gap is the article.

Where the molecule came from

Thymosin Alpha-1 is a 28-amino-acid peptide cut from a longer pro-protein the thymus produces during T-cell maturation. Allan Goldstein characterised it in 1977 at George Washington University, working through a set of thymic peptides that seemed to regulate immune function from outside the thymus.

The biology made sense from the start. The thymus is where naive T-cells learn to recognise antigens. The peptides it secretes act as messengers, carrying this is the kind of immune response we need signals out to the rest of the lymphocyte population. If you isolate and synthesise one of those messengers, you have, in principle, a drug that can push immune function in a specific direction without dragging along the rest of the thymic apparatus. Tα1 was the cleanest candidate.

Garaci’s 2007 historical overview, written from the Italian side of the Tα1 development, walks through how the molecule moved from biochemistry to clinical use. It got registered in over thirty countries as Zadaxin (thymalfasin) — chronic hepatitis B in Asia and the Middle East, hepatitis C as an interferon adjunct, certain oncology supportive-care settings. Then mechanism work confirmed that Tα1 increased MHC class-I expression, modulated Toll-like receptor signalling, shaped dendritic cell function. Solid translational story.

What the modern human file actually shows

Tα1 has more controlled human trial data than almost any peptide in this market. The most recent one is a null result.

The 2025 trial is TESTS, published in the BMJ. Wu and colleagues randomised 1,106 adults with sepsis across 22 Chinese ICUs to Tα1 or placebo, twice daily for seven days. Sepsis is the exact indication Tα1’s mechanism predicts: a dysregulated immune response where the patient is simultaneously inflamed and immunosuppressed, and the bottleneck on survival is the T-cell response. If Tα1 was going to work anywhere, it should have worked here.

It did not. 28-day mortality was 23.4% on Tα1 versus 24.1% on placebo. The hazard ratio came back at 0.99, with a confidence interval crossing the line of no effect, and a p-value of 0.93. The trial’s own conclusion was that there is no clear evidence Tα1 reduces mortality in sepsis. A prespecified subgroup analysis went further and hinted at harm in patients under 60 — hazard ratio 1.67, p for interaction 0.01.

That is the strongest, most recent test of Tα1 in its most mechanistically obvious indication, and the result is null with a possible subgroup signal of harm in the younger half of the patient population. The trial was co-funded by SciClone Pharmaceuticals — the molecule’s commercial sponsor — and most lead authors disclosed SciClone grants in the competing-interests declaration. It was still negative. That is the more credible kind of negative, not the less.

Soeroto and colleagues, writing in Inflammopharmacology in 2023, pulled together what had emerged from the COVID-19 cycle. Eight studies, moderate-to-critical patients, Tα1 versus standard care. The headline finding was a reduction in mortality (RR 0.59, 95% CI 0.37–0.93, p=0.02). The honest read is the secondary finding — statistical heterogeneity across the included trials was very high (I² = 84%), which is the meta-analyst’s signal that the underlying studies were measuring different things or running on different patient populations. The pooled effect is real on paper. Whether it survives a TESTS-quality individual COVID trial is unsettled — and given what TESTS did to the sepsis read, the prior should be that it might not.

Sherman’s 2010 review in the Annals of the New York Academy of Sciences sets the older comparison. By 2010 there was extensive Tα1 work in hepatitis C as an interferon adjunct, and Sherman’s verdict — promise and proof in the title — was honest. The molecule’s plausibility for HCV was high; the controlled trials had not conclusively supported it in combination interferon-based therapy at that point. The HCV picture is less central now because the standard of care moved on to direct-acting antivirals. The principle holds: a plausible mechanism is not a confirmed effect.

That is more human data than nine of the other ten peptides on this menu. It is concentrated in seriously ill patients. And the freshest, best-powered trial in the set came back negative.

Where the longevity case lives — and does not

This is where the gap between the science and the longevity market opens.

The Simonova 2025 review in the International Journal of Molecular Sciences is the most recent published case for Tα1 in aging. The biology it lines up is reasonable. The thymus shrinks with age in a process called thymic involution. Naive T-cell output drops. Immunosenescence makes older immune systems both less responsive to new threats and more inclined to low-grade chronic inflammation. Tα1, the molecule that helped orchestrate T-cell maturation in the first place, is a defensible candidate for partially reversing some of that decline.

The Simonova review walks through this mechanistic case carefully. What it does not include is what would close the loop: a randomised placebo-controlled trial of Tα1 in healthy older adults with measured immune-aging endpoints. The trial does not exist. Every controlled trial in the human Tα1 record was run in patients with a defined disease — hepatitis, sepsis, cancer adjunct, COVID. The case for healthy-adult longevity use is the mechanism makes sense and the drug is well-tolerated in sick people. That is not nothing. It is also not a clinical trial.

The implication is uncomfortable. If you are buying Tα1 to push back against age-related immune decline, you are buying a peptide with one of the deepest clinical records on this menu, in clinical contexts that are not yours.

The one-lab problem, partly

Tα1 has had a more diversified research history than BPC-157 or GHK-Cu. The molecule has been developed in Italy through Garaci’s group, registered through SciClone Pharmaceuticals internationally, studied in Russian academy contexts, and now run through Chinese ICUs in TESTS. That is genuinely independent replication across institutions, which is more than most peptides in this space have.

It is not the same as Western FDA-style replication of a longevity-specific claim. The TESTS trial settled a sepsis question with a null. The COVID meta-analysis settled a peri-pandemic question against a heterogeneity flag big enough to drive a truck through. The hepatitis B registrations settle a chronic-viral-infection question that does not generalise. None of those is the healthy 50-year-old chasing an immune edge question that the supplement scene is buying Tα1 for.

That is the cleaner read on the one-lab problem here. The lab problem is solved. The relevance problem is not.

The regulatory inheritance: biologics, not bulks

Tα1 is not on the July 23–24, 2026 FDA Pharmacy Compounding Advisory Committee docket. And it is not on the Feb 2027 second-wave docket either. But it is not outside the PCAC process — it already went through it. The FDA reviewed Tα1 in 2024. After it was removed from the Category 2 list in September 2024 and referred to PCAC, the committee evaluated it at the December 4, 2024 meeting and voted against inclusion on the 503A bulk drug substances list. The agency’s stated reasoning was the standard pattern: insufficient human safety data, mechanistic concerns, and lack of reproducible efficacy data outside small or open-label trials.

There is also a structural complication that runs alongside the procedural one. Tα1 sits under biologics regulation, not under the 503A small-molecule bulk-substances framework. A biologic in the US generally needs either a full Biologics License Application or an investigational new drug pathway. Both are a higher regulatory bar than 503A compounding. So even if the 2024 PCAC vote had gone differently, the compounding lane would have been constrained differently than for the small-molecule peptides on the July 2026 or Feb 2027 dockets.

Zadaxin — the marketed Tα1 product — is approved in dozens of countries but is not sold in the US as a commercial drug product. US use through compounding pharmacies sits in unresolved regulatory space that the cosmetic and bulk-substances frameworks both fail to settle cleanly. Anyone telling you the regulatory path for Tα1 in the US is fine is overstating it.

For WADA, the picture is direct. The 2026 Prohibited List S2 category — peptide hormones, growth factors, related substances and mimetics — covers Thymosin Alpha-1. Prohibited at all times, in and out of competition. The FDA’s biologics framing does not carry across to anti-doping; the S2 read is the operative one for athletes.

What would actually settle the longevity question

If you wanted Tα1 to be a credible longevity intervention rather than an off-label extrapolation, here is the evidence that would close the gap.

A randomised placebo-controlled trial of Tα1 in healthy older adults — say, 60 to 75 — with measured immune-aging endpoints. Vaccine response. Naive T-cell counts. Inflammatory markers. CMV reactivation rates. None of these are exotic measurements. None of these trials has been published.

A pharmacokinetic study in healthy adults defining what a sensible dose looks like outside the cancer adjunct or sepsis context. Not yet published.

A long-term safety read on chronic Tα1 use in healthy adults, characterising whether sustained immune-stimulation has cost as well as benefit. Years of dosing in a population that does not have a disease has not been studied.

And, given Tα1’s biologics status, a clean US regulatory path. That is the slowest of the four, because it depends on the FDA biologics pipeline rather than on the PCAC docket that other peptides on this menu are riding.

Where Tα1 lands today

The biology is real. The thymus shrinks with age. T-cell output drops. Tα1 is a real immunomodulatory peptide that your own thymus secretes, and it has been registered as a drug in dozens of countries for hepatitis B, hepatitis C, and oncology supportive care.

The trials, when you read them, are concentrated in sick people. The freshest of those — TESTS in sepsis, the indication Tα1’s mechanism predicts hardest — came back null, with a possible signal of harm in patients under 60. The COVID meta-analysis that looked positive has heterogeneity caveats that a single TESTS-scale trial could erase tomorrow. The hepatitis registrations sit a generation back, in patient populations that look nothing like a healthy 50-year-old.

The longevity application is the part the supplement market is selling, and it is the part nobody has run a controlled trial on. That gap is wider than the marketing implies, and it is wider after TESTS than it was before.

Tα1 is, on the published record, the peptide on this menu with the deepest clinical résumé and the most recent flagship negative. Both of those things are true at the same time. Both belong in the same sentence.

The honest place to be is patient. The next big read is whether a Western or independent group runs a TESTS-style trial in a healthier population for a longevity-adjacent endpoint, and whether the US biologics path eventually opens at all. Until then, what you can buy off a research-chemical site is a peptide that just failed its most demanding clinical test, sold for an indication it has never been tested in.

That is what we are building toward. Wolverine Health is a physician-supervised peptide service — real prescriptions, US-licensed compounding pharmacies, every batch third-party tested. It isn’t live yet, because the regulation isn’t either, and we’re not going to sell you ahead of the science. If you want to know the moment a legitimate US biologics path opens for Thymosin Alpha-1 — with the same honesty you just read, TESTS result included — join the waitlist.